HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Hunan Xizi Health Group - Weak Profitability Is a Pain Point

Pre-IPO Suplay - The Business Model, Peer Comparison and the Outlook

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

Equity Capital Markets

DKE Holding Company / Equity Capital Markets

<ul>
<li>DKE has seized the favorable opportunity in e-paper industry. However, there are prominent structural weaknesses such as poor profit quality, high dependence on supply chain, and high customer concentration.</li>
<li>Although the industry's beta is high, its own alpha is weak. If DKE can only survive with marginal profits in a "tight spot", the story is ultimately difficult to complete.</li>
<li>Under the double pressure from both upstream and downstream, it is difficult to maintain or even increase gross margin in the long term. A comfortable valuation could be 20-30x P/E.</li>
</ul>


DKE has seized the favorable opportunity in e-paper industry. However, there are prominent structural weaknesses such as poor profit quality, high dependence on supply chain, and high customer concentration.
Although the industry's beta is high, its own alpha is weak. If DKE can only survive with marginal profits in a "tight spot", the story is ultimately difficult to complete.
Under the double pressure from both upstream and downstream, it is difficult to maintain or even increase gross margin in the long term. A comfortable valuation could be 20-30x P/E.


Pre-IPO DKE Holding Company (PHIP Updates) - How Much Real Value Does The "Leader" Actually Have?